Author: Fiona Craig

Blue Star Capital (LSE:BLU) has restructured its £1 million secured loan to blockchain payments portfolio company SatoshiPay by converting €543,634 of outstanding debt into two Simple Agreements for Future Equity (SAFEs). The agreements carry valuation caps of €3.5 million and €2.5 million, and, if fully converted at those levels, Blue Star expects its ownership interest in SatoshiPay to increase from roughly 50% to at least 58%. The company has also secured an option to invest up to an additional €500,000 in equity at a €10 million pre-money valuation.

Alongside the restructuring, SatoshiPay will repay €115,000 in cash, after which the loan will be considered fully settled and related security arrangements released. Blue Star said the transaction leaves it with adequate working capital through to the end of 2026 while removing the need for further fundraising in the current year. The revised structure also provides SatoshiPay with greater financial flexibility, allowing treasury resources to be directed toward Vortex-related initiatives and general working capital requirements, while strengthening Blue Star’s exposure to a core blockchain investment without immediate equity dilution at the portfolio company level.

More about Blue Star Capital

Blue Star Capital is an AIM-listed investment company focused on emerging technology sectors, particularly blockchain, digital payments and esports. Its portfolio includes SatoshiPay, a blockchain-based payments specialist; Dynasty Media & Gaming, a business-to-business gaming ecosystem provider; and Paidia, a gaming platform designed for female audiences.

Arkle Resources (LSE:ARK) has repositioned its strategy following the acquisition of four uranium exploration licences in Namibia’s Erongo Region, elevating uranium to a central role within its portfolio alongside existing lithium and zinc projects. The newly acquired licences are located near established uranium deposits including Trekkopje, Marenica and Rössing, where earlier sampling identified strong surficial and alaskite-hosted uranium anomalies. The company is fully funded to begin geophysical surveys and mapping in the near term, with drilling targeted for 2026 and a maiden resource estimate planned for 2027.

In Botswana, Arkle continues to advance three lithium brine prospecting licences covering a significant portion of the Makgadikgadi Salt Pans. Geophysical work and sampling suggest a broad shallow brine system containing lithium as well as commercially valuable magnesium, which could enable direct lithium extraction while providing a potential secondary revenue stream. The company is progressing an environmental impact assessment ahead of shallow drilling aimed at defining lithium concentrations and brine characteristics. Meanwhile, in Ireland, Arkle retains a 22.36% stake in the Stonepark zinc joint venture, located within one of Europe’s leading zinc regions. The project hosts an inferred high-grade resource adjacent to Glencore’s Pallas Green development, supporting the company’s diversified exposure to energy-transition metals.

Arkle’s outlook remains constrained by weak financial fundamentals, including the absence of revenue, widening losses and continued cash burn alongside declining equity levels. Technical indicators provide a partial offset, with the share price trading above key moving averages and supported by positive MACD momentum. However, valuation visibility remains limited due to negative earnings and the lack of a stated dividend policy.

More about Arkle Resources PLC

Arkle Resources PLC is a London-listed exploration company focused on energy transition metals, with projects spanning uranium, lithium and zinc across Namibia, Botswana and Ireland. Its strategy centres on commodities critical to clean energy generation and storage, offering exposure to uranium within a major African uranium belt, lithium brines in Botswana’s Makgadikgadi Salt Pans and high-grade zinc resources in Ireland’s established mining district.

Victoria PLC (LSE:VCP) said trading conditions remain difficult, reporting third-quarter revenue approximately 3% lower year on year, an improvement compared with the 7% decline recorded during the first half. The reduction was mainly linked to lower shipment volumes as rug manufacturing transitions from Belgium to Turkey. Excluding the rugs segment, third-quarter revenue declined by around 1.5%. Continued weak consumer confidence and softer retail footfall in January have led the board to revise expectations, now forecasting FY26 revenue to come in roughly 5% below FY25 levels and post-IFRS16 EBITDA of about £95 million, below previous market forecasts.

Management is prioritising initiatives aimed at improving profitability, including initial sales from a new ceramics production line in Spain, ongoing relocation of rug manufacturing to Turkey, and continued integration of its UK underlay and Australian operations. Alongside operational measures, the company is advancing several balance-sheet actions, such as progressing property disposals, tightening management of receivables and inventory, and engaging with lenders and capital providers on refinancing options, including plans relating to its 2028 senior secured notes.

Victoria’s outlook remains pressured by declining revenues and elevated leverage levels, reflecting ongoing financial strain. Technical indicators point toward a bearish trend, and valuation metrics remain unattractive due to weak profitability. While strategic initiatives outlined by management indicate potential longer-term improvement, they have yet to outweigh current operational and market headwinds.

More about Victoria

Victoria PLC is an international manufacturer and distributor of flooring products headquartered in Worcester, UK, and listed on AIM. The company designs and supplies carpets, rugs, underlay, ceramic tiles, luxury vinyl tiles, artificial grass and flooring accessories across markets in the UK, Europe, North America and Australia. Operating more than 30 sites and employing over 5,000 people, Victoria is Europe’s largest carpet producer and the leading underlay manufacturer in both Europe and Australia.

eEnergy Group (LSE:EAAS) has obtained a £1 million secured loan from Harwood Holdco Limited to strengthen working capital as it accelerates delivery of a large UK government-supported solar PV and battery installation programme overseen by Mace. The project scope is being expanded to include as many as 73 schools, with additional LED lighting and electric vehicle charging installations now incorporated, and completion targeted for 30 June 2026.

The financing is designed to cover short-term peak working capital requirements as the company transitions from a traditional direct sales approach toward larger, longer-term contracts. This shift includes participation in an expanding pipeline of sizeable tender opportunities. Management noted that the facility enhances liquidity and balance sheet flexibility, while the group remains on track to approximately double first-half 2026 revenue to around £20 million, reflecting growing traction in higher-value infrastructure contracts despite reduced cash levels at year-end.

The company’s outlook continues to be influenced by weak financial performance and soft technical indicators. Although recent corporate developments provide some positive momentum, they do not fully offset ongoing financial and operational pressures. Valuation metrics remain challenged by a negative price-to-earnings ratio and the absence of dividend income.

More about eEnergy Group

eEnergy Group plc is a UK-based Energy-as-a-Service provider focused on financing and delivering energy efficiency and generation solutions for multi-site public sector and commercial customers, particularly within the education sector. Its core services include LED lighting upgrades, solar photovoltaic systems, battery storage and EV charging infrastructure, delivered through dedicated financing structures and public procurement frameworks, positioning the company as a green infrastructure partner for schools and institutional clients.

Helix Exploration (LSE:HEX) has initiated gas production at its flagship Rudyard Project, becoming the first company to produce helium in Montana and marking a key milestone as it moves from exploration into revenue-generating operations. Initial production is being delivered from three wells connected to a pressure swing adsorption processing plant, with output expected to increase as operational efficiencies improve and a fourth well, Inez, is brought online following completion of testing.

The commencement of production supports ongoing discussions with prospective offtake partners, with Helix aiming to secure a combination of short- and long-term sales agreements to optimise pricing and revenue stability. Although additional testing at the Inez well has been temporarily delayed due to drilling equipment issues, the company said the underlying helium and hydrogen resource potential remains unaffected, reinforcing confidence in the project’s long-term development prospects.

More about Helix Exploration Plc

Helix Exploration PLC is a helium exploration and development company focused on the Montana Helium Fairway in northern Montana. The group targets helium and nitrogen production from the Souris and Red River formations at its Rudyard Project, utilising existing infrastructure and cost-efficient processing solutions to build scale and generate near-term cash flow for industrial gas markets.

Trellus Health (LSE:TRLS) has completed the conversion of approximately £65,000 in principal and accrued interest from its secured convertible loan notes into equity, issuing 16,804,593 new ordinary shares. The transaction finalises the conversion of the company’s first tranche of notes, with the new shares expected to commence trading on AIM around 25 February 2026.

Following admission, Trellus Health’s total issued share capital will increase to 208,719,361 ordinary shares, establishing a revised reference point for shareholder voting rights and disclosure obligations under UK market transparency regulations. The conversion simplifies the company’s capital structure and modestly lowers its debt position by removing the converted loan notes.

The updated voting rights total will allow investors to assess whether notification requirements apply to their holdings or any changes in ownership, improving clarity around significant shareholdings in the company.

Trellus Health’s outlook remains constrained by weak financial fundamentals, including substantial ongoing losses, negative free cash flow and declining equity levels, despite the benefit of operating without debt. Technical indicators provide a more positive signal, with strong price momentum above key moving averages, although valuation support remains limited given continued losses and the absence of a dividend yield.

More about Trellus Health PLC

Trellus Health plc is a healthcare technology company offering Trellus Elevate, a digital, value-based condition management platform that combines data analytics with personalised, resilience-focused care programmes for complex chronic diseases. The company initially targets gastrointestinal conditions such as inflammatory bowel disease and collaborates with pharmaceutical partners to support clinical trials and commercialisation through patient engagement and adherence solutions.

International Public Partnerships (LSE:INPP) has completed the disposal of a 49% minority interest in the Moray East Offshore Transmission Owner (OFTO) project to Daiwa Energy & Infrastructure, generating proceeds of approximately £42 million. The transaction was agreed at a premium to the asset’s most recent valuation, while INPP retains a 51% controlling stake and majority board representation.

The sale forms part of the company’s ongoing capital recycling programme, under which around £387 million has been realised since mid-2023. Proceeds are primarily intended to fund INPP’s investment commitment to the Sizewell C nuclear project and to support its active share buyback initiative, reflecting a continued focus on disciplined capital allocation and balance sheet management as the company supports long-term energy transition infrastructure.

INPP’s outlook is underpinned by strong cash generation and a resilient balance sheet, although these positives are partly offset by a weaker income statement performance in 2024 and valuation metrics affected by a very high price-to-earnings ratio. Technical indicators remain modestly supportive, and recent corporate actions — including buybacks and strategic portfolio adjustments — provide some additional positive momentum.

More about International Public Partnerships

International Public Partnerships is a listed infrastructure investment company specialising in global public infrastructure assets that deliver social and environmental benefits. The group manages a diversified portfolio of more than 130 investments across sectors including utilities and energy transmission, transport, education, healthcare, justice and digital infrastructure, spanning the UK, Europe, Australia, New Zealand and North America, with a focus on long-term income generation and capital growth.

Hemogenyx Pharmaceuticals (LSE:HEMO) has secured £118,632 in new funding following the exercise of warrants covering 50,841 ordinary shares, with conversion prices ranging from 180p to 350p per share. The newly issued shares are set to be admitted to the FCA’s Official List and begin trading on the London Stock Exchange’s Main Market, bringing the company’s total issued share capital and voting rights to 6,425,429 shares.

After admission, shareholders should reference the updated share count when assessing disclosure requirements under FCA transparency regulations. While the capital raise represents a relatively small equity issuance, it modestly enhances the company’s financial position and may help support continued development of its clinical-stage pipeline, though it results in slight dilution for existing investors.

Hemogenyx’s outlook remains primarily constrained by weak financial fundamentals, including the absence of revenue, ongoing operating losses and continued cash burn, alongside elevated balance-sheet risk linked to lower equity levels and higher leverage. Technical indicators show strong recent momentum, partially offsetting concerns, although overbought signals introduce potential short-term volatility. Valuation support remains limited due to a negative price-to-earnings ratio and the lack of dividend income.

More about HemoGenyx Pharmaceuticals Plc

HemoGenyx Pharmaceuticals plc is a London-based clinical-stage biopharmaceutical company listed on the LSE under the ticker HEMO. Operating through U.S. subsidiaries in New York City, the group develops innovative medicines, therapeutic candidates and platform technologies aimed at treating blood disorders and autoimmune diseases, targeting areas with significant unmet medical need.

Cizzle Biotechnology (LSE:CIZ) has reported further progress toward the U.S. rollout of its CIZ1B blood test designed for early detection of lung cancer, as its North American partner, Cizzle Bio Inc., moves closer to completing validation work with Omni Health Diagnostics in Texas. The programme is advancing toward a planned application for CLIA accreditation expected in the second quarter of 2026.

The companies have also updated their financial agreement, confirming that Cizzle Biotechnology will receive the remaining US$1.81 million of initial advance royalty payments by the end of 2026. In addition, the revised terms include a guaranteed minimum of US$3.5 million in royalty income beginning in 2031, bringing total contracted revenue linked to the partnership to at least US$5.9 million and providing longer-term financial visibility as the test is introduced across North America.

Despite operational progress, the company’s outlook remains constrained by weak financial fundamentals, including its pre-revenue status, continuing losses, ongoing cash consumption and a significantly reduced equity base. Technical indicators also suggest limited market momentum, while valuation support remains minimal due to negative earnings and the absence of dividend payments.

More about Cizzle Biotechnology Holdings PLC

Cizzle Biotechnology Holdings PLC is a UK-based diagnostics developer focused on early cancer detection technologies. Its lead product is a non-invasive blood test built around the CIZ1B biomarker, which is strongly associated with early-stage lung cancer. The company primarily commercialises its technology through licensing agreements and royalty-based collaborations with partners and cancer care providers.